人胎盘核糖核酸酶抑制因子研究

人胎盘核糖核酸酶抑制因子研究崔秀云,田余祥（大连医科大学,大连１１６０２３）关键词人胎盘核糖核酸酶抑制因子人胎盘核糖核酸酶抑制因子（ｈｕｍａｎｐｌａｃｅｎｔａｌｒｉｂｏｎｕｃｌｅａｓｅｉｎｈｉｂｉｔｏｒ,ＰＲＩ）是一种酸性胞溶性蛋白质,分子量为５０ｋ...     

失配双链核糖核酸抑制柯萨奇B3病毒感染细胞的研究

通过药物抑制病毒致细胞病变效应实验和药物对病毒空斑形成抑制实验,研究低毒性失配双链核糖核酸（Poly I：C12u）和已知的抗病毒药物双链核糖核酸聚肌胞（Poly I：C）在细胞水平对柯萨奇病毒感染的抑制作用比较,证明Poly I：C12U的抗病毒作用。实验结果表明Poly I：C12U和Poly I：C均可有效地抑制病毒空斑的形成,且量效关系已确定。     

精氨酸对牛胰核糖核酸酶氧化复性的时相性抑制作用

精氨酸常在重组蛋白的体外复性中,作为一种小分子添加剂用于抑制蛋白聚集。精氨酸对蛋白复性折叠过程本身的影响尚不清楚。首次以不易聚集的牛胰核糖核酸酶为研究对象,通过飞行质谱检测氧化复性中间体的变化,通过酶学活性检测蛋白活性的恢复过程,观察了精氨酸对氧化复性的直接影响。发现不同浓度精氨酸对牛胰核糖核酸酶的氧化复性有直接的抑制作用。特别在0.5 mol/L浓度时,精氨酸对牛胰核糖核酸酶氧化复性的抑制作用具有独特的时相依赖性:早期复性可持续至4 h,其活性恢复达30%后,晚期复性基本终止。这种抑制特征与脲的抑制作用有明显的不同,精氨酸没有完全抑制关键结构中间体的形成。结果说明,牛胰核糖核酸酶的氧化复性,除经关键结构中间体的主要通路外,还可能存在一个潜在复性通路,它是其氧化复性后期的关键限速通路。该复性通路可以被0.5 mol/L精氨酸完全阻断。     

艾氏腹水癌细胞核糖核酸体外对C_(57)BL/6脾自然杀伤活性的影响

本文采用~(51)Cr释放法,研究了艾氏腹水癌细胞核糖核酸(EAC-RNA)体外对C_(57)BL/6小鼠脾自然杀伤细胞(NK)对YAC-1靶细胞杀伤活性的影响。结果表明,EAC-RNA能显著抑制NK活性。经RNase处理后,其抑制活性消失,DNase或Pronase的处理不改变其抑制活性。     

乙型肝炎病毒靶向核糖核酸酶及其突变体的原核表达和活性分析

目的：研究原核表达的乙型肝炎病毒（HBV）靶向核糖核酸酶（RNase）及其突变体（点突变失去RNase活性）的活性。方法：将构建的靶向核糖核酸酶及其突变体基因克隆入原核表达载体pET32a（＋）,转化大肠杆菌BL21（DE3）,以IPTG诱导融合蛋白（HBV核心蛋白与人嗜酸性粒细胞来源的神经毒素的融合蛋白）的表达;表达产物经包涵体纯化、SDS-PAGE和Western印迹鉴定,将纯化的蛋白用透析方法复性;以酵母tRNA为作用底物,应用复性的蛋白进行RNase活性分析。结果：纯化和复性了HBV靶向核糖核酸酶及其突变体;复性的HBV靶向核糖核酸酶可以降解酵母tRNA且具有剂量依赖性,而复性后的突变的靶向核糖核酸酶体不具有RNase活性。结论：原核表达的HBV靶向核糖核酸酶具有较强的RNase活性,为探索HBV靶向核糖核酸酶抑制乙肝病毒复制的机理奠定了基础。     

栝楼核糖核酸酶的性质研究

关于栝楼核糖核酸酶的性质已经研究.它对核糖核酸和多聚尿嘧喧核苷酸所显示的酶活性,有很大的相似性:(1)栝楼核糖核酸酶的最适度应pH在5左右;(2)稳定的pH范围在5-12之间;(3)最佳反应温度为55℃左右;(4) 热稳定性:在15分钟内,60℃以下酶活性基本稳定,在65℃左右时大约有50%的活性丧失;(5)金属离子中,除CU~(2+)和Ag~+有明显的抑制作用外、一般作用不明显.另外,酸对其它合成的多聚核苷酸的水解作用,显示有碱基特异性;对双链RNA(CPV RNA)也显有活性.实验中未发现该酶有磷酸单酯酶的活性及降解DNA的活性.因此,该酶可能是一种具有碱基特异性的核糖核酸酶.     

核糖核酸酶抑制因子对血管生成素功能的调控

血管生成素（angiogenin,ANG）能有效促进血管生成和肿瘤细胞增殖,在肿瘤发生发展中起重要作用.其主要分子机制是通过核转位和激活PI3K/AKT/mTOR信号通路,刺激rRNA转录和核糖体生成.ANG也被发现在肌萎缩侧索硬化症（ALS）和帕金森病（PD）患者中存在基因编码区的功能突变,表明其在运动神经元生理方面发挥作用,其缺陷是神经退行性疾病的一个危险因素.核糖核酸酶抑制因子（ribonuclease inhibitor,RI）是胞内酸性蛋白质,由460个氨基酸残基组成,分子质量约为50 kD,当其与核糖核酸酶A（RNaseA）结合形成复合物后,可抑制RNaseA 的90％以上活性,从而有效调节细胞内RNA水平. ANG具有低核糖核酸酶活性, 是RNase超家族一员,与RNase A有着高度保守的同源顺序. 序列、结构和酶学等分析表明,RI也能够与ANG紧密结合,且得到体外实验的证明. 研究发现,RI具抑癌基因功能;RI与ANG在细胞内共定位;Co IP和GST pull down证实其相互作用,获取了RI与ANG在体内结合的直接证据;RI与AKT磷酸化表达负相关.在膀胱癌细胞及临床标本中证实了RI与 ANG和PI3K/AKT通路分子表达的相关性及与肿瘤细胞生长与转移的关系．在细胞和动物模型研究表明,RI调节ANG活性的功能及其分子机制,即RI通过结合ANG而封锁其核转位和调控PI3K/AKT/mTOR信号通路及其相关通路交互应答（cross talk）的能力,从而抑制肿瘤生长及转移. RI是一个有希望的抗肿瘤蛋白新药和血管生成抑制剂,可望成为基因治疗的靶基因.     

水稻胚乳中核糖核酸的分离

核糖核酸(RNA)是分子生物学研究的重要材料之一。northern blot分析、构建cDNA库、分离基因和研究基因的转录调控都需要从细胞中分离RNA。从高等植物组织中分离高质量的RNA过程中既要防止外源核糖核酸酶的污染,同时也要注意内源核糖核酸酶的灭活。水稻胚乳细胞是种子储藏营养物质的主要部位。富含多糖类物质:如淀粉、糊精和一些低分子糖     

核糖核酸酶抑制因子(RI)的融合表达与复性

应用PCR技术从核糖核酸酶抑制因子 (ribonucleaseinhibitor ,RI)的克隆载体pT7 ri中扩增出ri片段 (1 5kb) ,亚克隆到融合表达载体pGEX 2T中 ,并转化感受态大肠杆菌BL2 1.异丙基半乳糖苷 (IPTG)诱导表达的GST RI经SDS PAGE证明分子量约 76kD ,表达量约占菌体蛋白总量 2 0 % .以包涵体形式表达的目的蛋白经尿素变性 ,透析复性得到的产物具有较高的抑制RNaseA的活性(15 0U ml) .复性的融合蛋白于 2 4℃经凝血酶作用 16h ,可被切割成 5 0kD的RI和 2 6kD的GST .     

核糖核酸酶抑制因子的制备及其在红细胞中的检测

应用Sepharose-RNase亲和层折柱从人胎盘中分防核糖核酸酶抑制因子(RI),纯化约1000倍,得率为43％。纯RI与Freund佐剂1:1稀释,免疫家免,获得抗血清,效价为1:8。经琼脂糖双扩散法和免疫分析,证明红血球中有特异性RI。存在于红细胞胞浆中,红细胞膜上不存在RI。     

The electrochemical interactions of heparin and the aminoglycoside antibiotics

Various aminoglycoside antibiotics—tobramycin "analytical standard"; tobramycin, gentamycin, kanamycin, and amikacin, all containing preservatives added in pharmaceutical preparations; and streptomycin—without preservatives—yield in aqueous solutions a conductance peak when titrated against a heparin aqueous solution, indicating the formation of a charge transfer complex, which subsequently dissociates. At the volume ratio corresponding to the peak, a colloidal suspensoid forms which is possibly a micellar complex stabilized by the ions produced by the dissociation of the complex. The clinical significance of this interaction is suggested by preliminary microbiological tests. The possible effects of plasma protein binding and dissociation of the complexes here reported in tissues, however, were not studied.In the interaction with heparin, the aminoglycoside antibiotics appear to act as electron acceptors, though heparin is reported to act as an acceptor against chlorpromazine, which is well known to be a strong electron donor. There appears to be an interaction between nonpreserved tobramycin and the preservative added for the pharmaceutical preparation, which would explain the difference in titration behavior between the antibiotic alone and the antibiotic with preservative.Conductance titrations of heparin against penicillin and cloxacillin, which are not aminoglycosides, show no evidence of complexation or any other interaction. No suspensoid forms.     

A method to determine the affinity of heparin to thrombin and antithrombin III on equilibrium gel permeation chromatography

Equilibrium gel permeation chromatography was employed to determine the ability of heparin to form complexes with thrombin and antithrombin III. In the eluate from a Sephacryl S-200 column, heparin caused a peak and then a trough in the fluorescence of 48 nM antithrombin III or 63 nM thrombin. The peak-heights with known amounts of heparin were used for standard curves to determine the extent of complex formation by test heparin preparations. Only heparin species with high-affinity for antithrombin III specifically formed a complex with antithrombin III under the conditions used. The ability to form a complex of heparin preparations with different anticoagulant activities for thrombin and antithrombin III could be determined satisfactorily. The heparin species with different affinities for antithrombin III did not coincide those with different affinities for thrombin. Of 4 preparations with one low-affinity and three high-affinity subfractions of heparin for antithrombin III, the species with the lowest affinity for antithrombin III had the highest affinity for thrombin. All of these observations showed that the method could be used to determine the ability to form a complex of test heparin preparations.     

Molecular weight determination of heparin and dermatan sulfate by size exclusion chromatography with a triple detector array

The determination of molecular weight (M) and molecular weight distribution (MD) of heparins by a novel approach, consisting of a high performance size exclusion chromatography (HP-SEC) combined with a triple detector array (TDA) is described. HP-SEC/TDA permits the evaluation of MD of polymeric samples through a combined and simultaneous action of three on-line detectors, right-angle laser light scattering (RALLS), refractometer (RI), and viscometer. The method does not require any chromatographic column calibration, thus overcoming also the difficulty to obtain adequate reference standards. It permits the size determination also of small molecules, even when scattering dissimmetry is not observable. Unfractionated heparins, eight fractions of a size fractionated heparin, and dermatan sulfates were analyzed by HP-SEC/TDA. The M values found for the heparin fractions were used to build up a calibration curve of a conventional HP-SEC system: the results obtained analyzing unfractionated heparin samples with both HP-SEC/TDA and HP-SEC were in excellent agreement, suggesting the possibility to use the TDA data to generate standard samples with known MD and intrinsic viscosity [eta]. Moreover, HP-SEC/TDA can successfully be employed also for the determination of the Mark-Houwink a and k parameters.     

Importance of the spatial display of charged residues in heparin–peptide interactions

Many studies have examined consensus sequences required for protein‐glycosaminoglycan interactions. Through the synthesis of helical heparin binding peptides, this study probes the relationship between spatial arrangement of positive charge and heparin binding affinity. Peptides with a linear distribution of positive charge along one face of the α‐helix had the highest affinity for heparin. Moving the basic residues away from a single face resulted in drastic changes in heparin binding affinity of up to three orders of magnitude. These findings demonstrate that amino acid sequences, different from the known heparin binding consensus sequences, will form high affinity protein‐heparin binding interactions when the charged residues are aligned linearly. © 2009 Wiley Periodicals, Inc. Biopolymers 93: 290–298, 2010. This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com     

In vitro development of rat embryos undergoing organogenesis in heparin-plasma.

This study examines the use of heparin-plasma as a culture medium for mammalian postimplantation whole-embryo culture. The growth and differentiation of head-fold rat embryo explants over 48 hours in a standard serum medium was compared with development of same stage explants over 48 hours in a plasma medium prepared using sodium heparin. Heparin disrupted the morphological differentiation of embryos, in a concentration-dependent manner, from 25 micrograms sodium heparin/ml media (i.e., 5 IU/ml media), with overall embryo growth being adversely affected from a concentration of 200 micrograms sodium heparin/ml media (i.e., 40 IU/ml media). Defects of cranial neural tube development were the first apparent structural anomalies resulting from culture in heparin media. Forebrain development was grossly abnormal and associated with failure of eye development. As the heparin concentration in media increased, the cephalic neural folds remained widely open and the edges became increasingly everted, although differentiation of the heart, otic primordia, and pharyngeal arch persisted. Similar concentration-dependent dysmorphogenic effects were seen when embryos were cultured in the standard serum media with added heparin. A minimum heparin concentration of 100 micrograms sodium heparin/ml media (i.e., 20 IU/ml media) was required to effectively inhibit coagulation of the plasma medium over the 48 hour culture period. Although embryonic growth was not adversely affected at this heparin concentration, morphological differentiation was severely disrupted. Therefore, heparin is not a suitable anticoagulant for the preparation of plasma for use in postimplantation whole-embryo culture.     

A new approach for heparin standardization: combination of scanning UV spectroscopy, nuclear magnetic resonance and principal component analysis

The year 2007 was marked by widespread adverse clinical responses to heparin use, leading to a global recall of potentially affected heparin batches in 2008. Several analytical methods have since been developed to detect impurities in heparin preparations; however, many are costly and dependent on instrumentation with only limited accessibility. A method based on a simple UV-scanning assay, combined with principal component analysis (PCA), was developed to detect impurities, such as glycosaminoglycans, other complex polysaccharides and aromatic compounds, in heparin preparations. Results were confirmed by NMR spectroscopy. This approach provides an additional, sensitive tool to determine heparin purity and safety, even when NMR spectroscopy failed, requiring only standard laboratory equipment and computing facilities.     

Heparin interactions with cultured human vascular endothelial and smooth muscle cells: incidence on vascular smooth muscle cell proliferation

The binding, internalization, and metabolism of [3H]-heparin by human umbilical vein endothelial cells (HUVEC) and human umbilical arterial smooth muscle cells (HUASMC) have been characterized using size-exclusion HPLC. Incubation of HUVEC with [3H]-heparin demonstrated selective binding of high-molecular-weight (MW) components (MW = 21 kd), which was followed by rapid, temperature-dependent internalization. Over the next 3 hours, this internalized [3H]-heparin was degraded to low-MW fragments (MW = 0.9 kd). Primary cultures of HUASMC selectively bound extremely high-MW components (MW = 40 kd) and also smaller components whose MW (0.9 kd) corresponded to that of the heparin metabolite(s) formed by HUVEC. Subcultured HUASMC bound only the 40-kd components. Internalization of heparin by smooth muscle cells (SMC) was significantly slower than that determined for HUVEC, and even after 4 hours there was no evidence of the heparin being metabolized. However, when incubating primary rabbit aortic SMC with purified low-MW heparin fragment(s) produced in culture by HUVEC, a significantly lower proliferative response of these cells (IC50 = 18.4 micrograms/ml) was obtained. Virtually no effect was observed with subcultured SMC in the range of the tested concentrations (0-20 micrograms/ml). These fragments were 10- to 15-fold more effective in inhibiting primary SMC growth than was standard heparin. Furthermore, heparin fractions in the same range of molecular weights, purified either after nitrous acid or heparinase depolymerization of standard heparin, showed no activity on primary SMC growth, thus indicating a high degree of selectivity of the heparin metabolite(s) produced by HUVEC in culture.     

Histidine-rich glycoprotein plus zinc reverses growth inhibition of vascular smooth muscle cells by heparin

Vascular smooth muscle cell (SMC) hyperplasia is known to be an important component in the pathogenesis of arteriosclerosis and restenosis. Although heparin has been well recognized as the representative molecule suppressing SMC growth in vitro, attempts to use heparin as a therapeutic anti-restenosis drug have not favorably influenced the angiographic or clinical outcome after angioplasty in some clinical trials. In this study, we have examined the effect of histidine-rich glycoprotein (HRG), a relatively abundant serum glycoprotein (~100 micrograms/ml in human serum), on the growth inhibition of cultured vascular SMC by heparin. Vascular SMC growth was significantly inhibited by heparin, giving nearly 85% inhibition with 100 micrograms/ml heparin. HRG reversed heparin-induced SMC growth inhibition in a dose dependent manner; 75% restoration of cell growth was observed when 100 micrograms/ml of HRG was co-added with 100 micrograms/ml heparin. Interestingly, micromolar concentrations of the zinc ion (0-10 microM), compatible with concentrations released from activated platelets, were found to enhance the restorative action of HRG. Western blot experiment demonstrated no significant amounts of the HRG moiety in fetal bovine serum, eliminating the possible contribution of contaminant HRG from culture media. These findings indicate that HRG, in combination with the zinc ion, plays a role in modulating the SMC growth response in pathophysiological states and explain the lack of success of heparin as a therapeutic anti-restenosis drug in clinical trials.     

Mechanism of inhibition of mammalian DNA topoisomerase I by heparin.

We have previously shown that heparin is a potent inhibitor of a mammalian DNA topoisomerase I. We have now investigated the mechanism of its inhibition. This was carried out first by scrutinizing the structural features of heparin molecules responsible for the inhibition. Commercial heparin preparation was fractionated by antithrombin III-Sepharose into non-adsorbed, low-affinity and high-affinity fractions, of which only the high-affinity fraction of heparin is known to contain a specific oligosaccharide sequence responsible for the binding to antithrombin III. These fractions all exhibited essentially similar inhibitory activities. Furthermore, when chemically sulphated to an extent comparable with or higher than heparin, otherwise inactive glycosaminoglycans such as heparan sulphate, chondroitin 4-sulphate, dermatan sulphate and neutral polysaccharides such as dextran and amylose were converted into potent inhibitors. Sulphated dermatan sulphate, one of the model compounds, was further shown to bind competitively to the same sites on the enzyme as heparin. These observations strongly suggested that topoisomerase inhibition by heparin is attributable primarily, if not entirely, to the highly sulphated polyanionic nature of the molecules. In a second series of experiments we examined whether heparin inhibits only one or both of the topoisomerase reactions, i.e. nicking and re-joining. It was demonstrated that both reactions were inhibited by heparin, but the nicking reaction was more severely affected than was the re-joining reaction.     

Tryptophan residue at the heparin binding site in antithrombin III

Chemical modifications have demonstrated that the ultraviolet difference spectrum produced when heparin interacts with antithrombin III is due primarily to changes in the tryptophan environment. This is based on the observation that this spectrum could be abolished by treatment of antithrombin III with dimethyl (2-hydroxy-5-nitrobenzyl) sulfonium bromide but not with tetranitromethane. The tryptophan-modified antithrombin III is still capable of binding to thrombin even when it has lost 85% of heparin cofactor activity. A marked decrease in reactivity of tryptophan residues is observed when modification is carried out in the presence of heparin. Evidence is presented that tryptophan is in the heparin binding site.